




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Contents lists available at ScienceDirect

European Journal of Internal Medicine

journal homepage: www.elsevier.com/locate/ejim

Letter to the Editor

Disguised aspects of IgG4

ARTICLE INFO

Keywords

COVID-19

IgG4

Immunoglobulins



Dear Editor,

We read with great interest a recently published study by Della-Torre, Lanzillotta et al. regarding IgG4 level in COVID-19 patients [1].

The conclusion which was drawn from the study that IgG4 predicts COVID-19 related mortality was quite far-reaching. Especially taking into account the number of enrolled patients (128 participants) and unique properties of IgG4 protein.

It is known that IgG4 levels may vary significantly in healthy individuals [2]. Additionally increased levels may be observed in various diseases such as allergies, cancer, vasculitis, rheumatoid arthritis, and many others [3]. Except for the history of diabetes and hypertension we do not know if any history regarding autoimmune diseases was collected from the patients. We also do not know the baseline level of IgG subclasses in enrolled patients before SARS-CoV-2 infection. It is possible that patients' IgG4 level was elevated due to another reason. We should not exclude the possibility that patients with elevated baseline IgG4 are more susceptible to a severe course of COVID-19.

A low number of study participants was noticed by the authors in the limitations. When the prevalence of a disease is as high as SARS-CoV-2 infection, studies should enroll more patients to increase the power of the study and make the conclusions more reliable. Although statistically significant, the results may still be clinically irrelevant.

Financial disclosure

None reported.

Ethical approval was not necessary for the preparation of this article.

Conflict of interests

The authors declare they have no conflict of interest.

References

- [1] Della-Torre E, Lanzillotta M, Strollo M, Ramirez GA, Dagna L, Tresoldi M. Serum IgG4 level predicts COVID-19 related mortality. *Eur J Intern Med* 2021. <https://doi.org/10.1016/j.ejim.2021.09.012>.
- [2] Nirula A, Glaser SM, Kalled SL, Taylora FR. What is IgG4? A review of the biology of a unique immunoglobulin subtype. *Curr Opin Rheumatol* 2011;23(1):119–24.
- [3] Konecny I. Update on IgG4-mediated autoimmune diseases: new insights and new family members. *Autoimmun Rev* 2020;19(10):102646. <https://doi.org/10.1016/j.autrev.2020.102646>.

Natalia Aleksandra Dułak*, Rafał Trzciński
 Department of Cardiology, Saint Vincent de Paul Hospital, Gdynia, Poland

* Corresponding author at: Department of Cardiology, Saint Vincent de Paul Hospital, 81-348 Gdynia, Wójta Radtkego 1, Poland.
 E-mail address: oladulak@gumed.edu.pl (N.A. Dułak).

<https://doi.org/10.1016/j.ejim.2021.10.016>

Received 8 October 2021; Accepted 12 October 2021

Available online 27 October 2021

0953-6205/© 2021 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.